

UNC Lineberger Cancer Network  
**ADVANCED PRACTICE PROVIDER** Live Webinar  
 February 15, 2023

Welcome to the  
**UNC Lineberger Cancer Network's**  
 live webinar

**Contact UNCLCN**  
 Phone: (919) 445-1000  
 Email: unclcn@unc.edu  
 Website: unclcn.org

Sound Check **3:55 PM** Start Time **4:00 PM**

Poll Everywhere is used for Q&A. More information at: [pollev.com/unclcn](http://pollev.com/unclcn)  
 For any technical difficulties: (919) 445-1000 [unclcn@unc.edu](mailto:unclcn@unc.edu)

While waiting, check out our upcoming webinars: [learn.unclcn.org/live](http://learn.unclcn.org/live)

Approved Public Provider webinars created and approved by: Nancy Nigam, PhD, APRN, AOCNP, AACCNP, FAHA, UNC Lineberger Cancer Network

1

---

---

---

---

---

---

---

---

---

---

**POLL EVERYWHERE**

Join by Web



- Go to [PollEv.com](http://PollEv.com)
- Enter UNCLCN
- Respond to activity

2

---

---

---

---

---

---

---

---

---

---

**TO CLAIM CE CREDIT**

Participants must attend using one of the following:

- Zoom with the slides and video components
- At a designated site with a site coordinator

The following do NOT qualify for CE credit:

- Joining Zoom using Phone audio only (using the Zoom Android or iPhone app is fine)
- Watching with MediaSite

To claim CE credit

- View 50 minutes or more
- Fill out an evaluation and select a certificate
- Claim credit within seven days

3

---

---

---

---

---

---

---


---

---

---

**AFTER THE WEBINAR**

To collect CE Credit,  
please wait for UNCLCN  
to end the Zoom video.



The Learning Portal only  
receives Zoom attendance data  
after the Zoom video has ended.

4

---

---

---

---

---

---

---

---

**CONTINUING EDUCATION CREDITS**

**FREE CE Credits with Live Webinars**  
*Only Available at the Day and Time Indicated*

<b>PATIENT CENTERED CARE</b> 2nd Wednesday Jan-Oct NCP/CNE 1st Wednesday Nov-Dec ACPE 12 pm - 1 pm ASRT CTR	<b>ADVANCED PRACTICE PROVIDER</b> 3rd Wednesday Jan-Oct NCP/CNE 2nd Wednesday Nov-Dec
<b>RESEARCH TO PRACTICE</b> 4th Wednesday Jan-Oct CME 3rd Wednesday Nov-Dec NCP/CNE NO RHP webinar in February ACPE 12 pm - 1 pm ASRT CTR	<b>SOUTHEASTERN AMERICAN INDIAN CANCER HEALTH EQUITY PARTNERSHIP</b> 1st Wednesday Feb, May, Nov CME 12 pm - 1 pm NCP/CNE

**FREE CE Credits with Self-Paced, Online Courses**  
*Available any Day and Time*

[learn.unclcn.org](http://learn.unclcn.org)

5

---

---

---

---

---

---

---


---

UNC Lineberger Cancer Network

**ADVANCED PRACTICE PROVIDER**

**February 15, 2023**

**Oral Chemotherapy:  
Prescribing, Monitoring, and Safety**



**Aimee Faso, PharmD, BCOP, CPP**

Progress indicator: 10 columns of 3 boxes each. The first 10 boxes in the first row are filled with a red circle, indicating 100% completion.

6

---

---

---

---


---

---

---

---

**OUR PRESENTER**



**Aimee Faso,**  
PharmD, BCOP, CPP

Aimee Faso, PharmD, BCOP, CPP, is a Clinical Pharmacist Practitioner (CPP) at the North Carolina Basnight Cancer Hospital (NCBCH) who works with the breast oncology team. After completing her Master's degree in physiological psychology at Ohio University, she worked in the pharmaceutical industry for 2 years. She then attended pharmacy school at the University of Florida in Gainesville, FL followed by a pharmacy practice residency at Dartmouth Hitchcock Medical Center.

Dr. Faso started working at the NCBCH in 2008 and in 2014 joined the outpatient breast oncology team. She is Adjuvant Faculty at the Eshelman School of Pharmacy where she teaches breast cancer treatment to pharmacy students and is a preceptor to pharmacy students and pharmacy residents. She is also a Clinical Assistant Professor in the School of Nursing where she teaches oncology pharmacology in the nurse practitioner program.

7

---

---

---

---

---

---

---

---

**OUR PRESENTER**

8

---

---

---

---

---

---

---

---

**OUR PRESENTER**

5. Preceptor to pharmacy students and pharmacy residents.

9

---

---

---

---

---

---

---

---

**OUR PRESENTER**

5. Preceptor to pharmacy students and pharmacy residents.
4. Clinical Assistant Professor in the School of Nursing where she teaches oncology pharmacology in the nurse practitioner program.

10

---

---

---

---

---

---

---

---

**OUR PRESENTER**

5. Preceptor to pharmacy students and pharmacy residents.
4. Clinical Assistant Professor in the School of Nursing where she teaches oncology pharmacology in the nurse practitioner program.
3. Adjuvant Faculty at Eshelman School of Pharmacy where she teaches breast cancer treatment to pharmacy students.

11

---

---

---

---

---

---

---

---

**OUR PRESENTER**

5. Preceptor to pharmacy students and pharmacy residents.
4. Clinical Assistant Professor in the School of Nursing where she teaches oncology pharmacology in the nurse practitioner program.
3. Adjuvant Faculty at Eshelman School of Pharmacy where she teaches breast cancer treatment to pharmacy students.
2. In 2014, joined Lineberger's outpatient breast oncology team.

12

---

---

---

---

---

---

---

---

**OUR PRESENTER**

5. Preceptor to pharmacy students and pharmacy residents.
4. Clinical Assistant Professor in the School of Nursing where she teaches oncology pharmacology in the nurse practitioner program.
3. Adjuvant Faculty at Eshelman School of Pharmacy where she teaches breast cancer treatment to pharmacy students.
2. In 2014, joined Lineberger's outpatient breast oncology team.
1. Since 2008, Clinical Pharmacist Practitioner at the North Carolina Basnight Cancer Hospital.

13

---

---

---

---

---

---

---

---

© Respond at [PollEverywhere.com/uncncln](https://PollEverywhere.com/uncncln)  
 or Text UNCLCN to 22333 once to join, then A or B

UNC Lineberger Cancer Network

Oral chemotherapy is a drug, normally a tablet or capsule, used to help kill or weaken cancer cells. The drug can be taken at home, versus in a hospital setting.

Powered by [Poll Everywhere](https://PollEverywhere.com)

14

---

---

---

---

---

---

---

---

**DISCLOSURES**

This activity has been planned and implemented under the sole supervision of the Course Director, William A. Wood, MD, MEd, in association with the UNC Office of Continuing Professional Development (CPD). The course director and CPD staff have no relevant financial relationships with ineligible companies as defined by the ACCME.

The University of North Carolina at Chapel Hill is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

A potential conflict of interest occurs when an individual has an opportunity to affect educational content about health-care products or services of a commercial interest with which he/she has a financial relationship. The speakers and planners of this learning activity have not disclosed any relevant financial relationships with any commercial interests pertaining to this activity.

15

---

---

---

---

---

---

---

---



16

---

---

---

---

---

---

---

---



17

---

---

---

---

---

---

---

---



18

---

---

---

---

---

---

---

---

### Oral chemotherapy

- Oral chemotherapy includes medications taken by mouth that are cytotoxic or target proteins, pathways or receptors that are involved with cancer
- Use of oral chemotherapy has been steadily increasing
  - 18 novel oral chemotherapies have been approved from 2020 to December 2022
  - Estimated that 25-30% of chemotherapy medications in the development pipeline will be oral

New Drugs at FDA: CDER's New Molecular Entities and New Therapeutic Biological Products. <https://www.fda.gov/drugs/development-approval-process-drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products>. Accessed December 8, 2022.  
Hematology/Oncology Pharmacy Association (HOPA). Oral chemotherapy issue brief. [www.hopax.org/images/hopa3dofocacy/issue-brief/HOPA\\_Oral\\_Chemotherapy\\_Issue\\_Brief.pdf](http://www.hopax.org/images/hopa3dofocacy/issue-brief/HOPA_Oral_Chemotherapy_Issue_Brief.pdf).

19

---

---

---

---

---

---

---

---

### Shifts the care of patients from the provider to the patient

<b>Benefits</b>	<b>Concerns</b>
<ul style="list-style-type: none"> <li>• Patient convenience</li> <li>• Patient empowerment</li> <li>• Reduced burden of care</li> <li>• Efficacious</li> <li>• Reduced toxicity?</li> </ul>	<ul style="list-style-type: none"> <li>• Adherence</li> <li>• Safety</li> <li>• Proper storage/handling</li> <li>• Monitoring</li> <li>• Cost</li> </ul>

Weingart SN, Toro J, Spencer J, et al. Medication errors involving oral chemotherapy. *Cancer* 116:2455-2464, 2020  
Weingart SN, et al. NCCN Task Force: Oral Chemotherapy. *J Natl Comp Canc Netw* 2008;6 Suppl 3:51-14.

20

---

---

---

---

---

---

---

---

### Wide scope of use

CML	• Imatinib, nilotinib, dasatinib, bosutinib
Metastatic RCC	• Sunitinib, pazopanib, cabozantinib, axitinib
Ph+ AML	• Imatinib, dasatinib (along with cytotoxic chemotherapy)
BRAF-mutant melanoma	• Vemurafenib/cobimetinib, dabrafenib/trametinib
ALK-mutant non-small cell lung cancer	• Crizotinib, alectinib, ceritinib
Multiple myeloma	• Thalidomide, lenalidomide containing regimens
EGFR-mutant NSCLC	• Erlotinib, afatinib, osimertinib, gefitinib
Advanced prostate Cancer	• Abiraterone, enzalutamide, apalutamide
Advanced breast cancer	• Tucatinib, capecitabine, ribociclib
Advanced colon cancer	• Capecitabine, regorafenib, trifluridine + tipiracil

21

---

---

---

---

---

---

---

---

Varied mechanisms of action

- Cytotoxic • E.g. Capecitabine
- Targeted • E.g. Imatinib
- Endocrine • E.g. Tamoxifen
- Other • E.g. Lenalidomide

22

---

---

---

---

---

---

---



**Oral Chemotherapy**  
PRESCRIBING

23

---

---

---

---

---

---

---

Prescribing  
Safe prescribing at the institutional level

Development of institutional policies and procedures

- Standardized ordering practices
- Standardized patient monitoring
- Standardized symptom management
- Consistent documentation

24

---

---

---

---

---

---

---



### Prescribing

Safe prescribing for patient care

**Review upon initiation of oral chemotherapy**

- Diagnosis
- Comorbid conditions and past medical history
- Comprehensive medication history and allergies
- Height/weight
- Functional or performance status
- Baseline labs

**Assess at initiation and at each encounter**

- Vital signs
- Weight
- Allergies
- Toxicities
- Medication review
- Functional status
- Labs, as appropriate

Neuss MN et al. 2016 Updated American Society of Clinical Oncology/Oncology Nursing Society Chemotherapy Administration Safety Standards, including Standards for Pediatric Oncology. JOP 2016;13(12):1262-1271.

---

---

---

---

---

---

---

---

---

---

25

### Prescribing

Oral chemotherapy prescriptions should include:

- Patient name and demographics
- Drug name
- Dose calculation, if applicable
- Schedule
- Administration instructions
- Quantity
- Refills

*Sample Prescription*

Name: Jane Doe  
 DOB: 11/19/63  
 MRN: 000000000  
 Address: 123 Main St,  
 Chapel Hill, NC 27514

Medical Center  
 100 Medical Center Dr.  
 Chapel Hill, NC 27594  
 T: 800-555-1232  
 F: 800-555-4343

Date: Feb. 2, 2023

Capecitabine 500 mg tablets

**Sig:** Take 3 tablets (1500 mg) po after breakfast and 3 tablets (1500 mg) po after dinner for 21 days of a 21-day cycle.  
**Qty:** 84 tablets    **Refill:** 0 (Zero)    **Route:** Oral

**Diagnosis:** Malignant neoplasm of right breast, female (C50.022)

**Pharmacy Note:** Wt=67 kg; Ht=160 cm BSA=1.73  
 Dose = 1000 mg/m<sup>2</sup> po BID x 14, days of 21 day cycle

---

**Authorizing Provider: Dr. Hemonc**  
 NPI: 2000000000  
 License # 100

---

---

---

---

---

---

---

---


---

---

26

### Patient education

- Patients should be provided education prior to initiation of oral chemotherapy
- Best to use standardized teaching materials
- Should be suitable for patient's health literacy and language
- Can clarify patient misconceptions
- Will need reinforcement throughout treatment period



Mackler, E et al. 2018 Hematology/Oncology Pharmacist Association Best Practices for the Management of Oral Oncolytic Therapy: Pharmacy Practice Standard. JOP 2018;15(4): e316-e335.

---

---

---

---

---

---

---

---

---

---

27

### Patient education

Diagnosis	Goals of treatment	Administration	Duration
Missed doses	Monitoring and follow-up	Side effects	Safe handling, storage, disposal
Drug-drug and drug-food interactions	Self-management strategies	When to seek medical attention	

Neuss MN et al. 2016 Updated American Society of Clinical Oncology/ Oncology Nursing Society Chemotherapy Administration Safety Standards, Including Standards for Pediatric Oncology. JOP 25(6):1212-1262-1277

28

---

---

---

---

---

---

---

---

### Patient education

Should also include

- Written care plan
- Specific administration instructions

Morning	Evening
7 am - Lapatinib (Tykerb)	--
8 am - Breakfast	8 pm - Dinner
8:30 am - Capecitabine (Xeloda)	8:30 pm - Capecitabine (Xeloda)

29

---

---

---

---

---

---

---

---

### Calendar

	Sun	Mon	Tue	Wed	Thu	Fri	Sat	
	30 (Cycle 7, Day 1) Ponatinib 15 mg Doxorubicin IV Dexamethasone 1.5 tabs in the morning and 1.5 tabs in the afternoon Mercaptopurine 1 tab	31 Ponatinib 15 mg Dexamethasone 1.5 tabs in the morning and 1.5 tabs in the afternoon Mercaptopurine 2 tabs	1 Ponatinib 15 mg Dexamethasone 1.5 tabs in the morning and 1.5 tabs in the afternoon Mercaptopurine 1 tab	2 Ponatinib 15 mg Dexamethasone 1.5 tabs in the morning and 1.5 tabs in the afternoon Mercaptopurine 2 tabs	3 Ponatinib 15 mg Dexamethasone 1.5 tabs in the morning and 1.5 tabs in the afternoon Mercaptopurine 1 tab	4 Ponatinib 15 mg Dexamethasone 1.5 tabs in the morning and 1.5 tabs in the afternoon Mercaptopurine 2 tabs		
	5 Ponatinib 15 mg Mercaptopurine 2 tabs	6 Ponatinib 15 mg Mercaptopurine 1 tab	7 Ponatinib 15 mg Mercaptopurine 2 tabs	8 Ponatinib 15 mg Mercaptopurine 1 tab	9 Ponatinib 15 mg Mercaptopurine 2 tabs	10 Ponatinib 15 mg Mercaptopurine 1 tab	11 Ponatinib 15 mg Mercaptopurine 2 tabs	
	12 Ponatinib 15 mg Mercaptopurine 2 tabs	13 Ponatinib 15 mg	14 Ponatinib 15 mg	15 Ponatinib 15 mg	16 Ponatinib 15 mg	17 Ponatinib 15 mg	18 Ponatinib 15 mg	
	19 Ponatinib 15 mg	20 (Cycle 8, Day 1) Ponatinib 15 mg Doxorubicin IV Dexamethasone 1.5 tabs in the morning and 1.5 tabs in the afternoon	Take mercaptopurine at least 1 hour after evening meals. Avoid milk and citrus products.					

30

---

---

---

---




---

---

---

---

Patient education

-  Education should be provided verbally and in written form
-  Education should include family members, caregivers or others
-  Patients should be encouraged to write down questions and answers

31

---

---

---

---

---

---

---

---

Patient education resources

- Website resources that provide handouts specifically for patients
  - Oncolink (<https://www.oncolink.org/>)
  - Chemocare (<https://chemocare.com/>)
  - Oral Chemotherapy Education (<https://www.oralchemoedsheets.com/>)
- Package insert
- Tertiary drug information databases
  - Lexi-Comp, UpToDate®, Facts and Comparisons, Micromedex
  - [www.drugs.com/monograph](http://www.drugs.com/monograph)
    - Free website that obtains drug information from multiple drug information databases including Micromedex and American Society of Health-System Pharmacists

32

---

---

---

---

---

---

---

---

Drug interactions

- Oral chemotherapy can interact with other medications, supplements, or foods
- Can result in increased toxicities or reduced efficacy
- Interactions may occur by multiple mechanisms
- Important to assess for interactions at each visit
- Information on interactions and their management may be limited

Segal EM et al. Oral chemotherapy food and drug interactions: A comprehensive review of the literature. J Oncol Pract 2015;11:e559-568  
Rogalski BD et al. Oral anticancer therapy: Management of drug interactions. J Oncol Pract 2015;11:81-90

33

---

---

---

---

---

---

---

---

**Pharmacokinetic drug interactions**

- Effect the absorption, distribution, metabolism or excretion of another drug
- CYP 3A4 is the most common enzyme that metabolizes oral chemotherapy
  - Drugs that inhibit or induce CYP 3A4 can effect concentrations of drugs that are substrates of this enzyme

**EXAMPLES**

- Phenytoin (Dilantin®)
  - Strong 3A4 inducer
  - Can significantly decrease the concentrations of medications that are major substrates of CYP 3A4
- Nirmatrelvir/ritonavir (Paxlovid®)
  - Strong 3A4 inhibitor
  - Can significantly increase the concentration of major substrates of CYP 3A4

Segal EM et al. Oral chemotherapy food and drug interactions: A comprehensive review of the literature. J Oncol Pract 2015;10:e255-268  
Rogala BD et al. Oral anticancer therapy: Management of drug interactions. J Oncol Pract 2015;15:81-90

34

---

---

---

---

---

---

---

---

---

---


**Pharmacodynamic drug interactions**

Lead to an alteration of pharmacologic effect, which may be additive, synergistic, or antagonistic

**EXAMPLE**

QTc prolongation

- Oral chemotherapy agents may prolong QTc and the addition of other drugs that have this side effect result in an additive risk
- Ribociclib (Kisqali®) can cause QTc prolongation. Addition of ondansetron (Zofran®) or citalopram (Celexa®) can increase the risk of this adverse effect



Segal EM et al. Oral chemotherapy food and drug interactions: A comprehensive review of the literature. J Oncol Pract 2015;10:e255-268  
Rogala BD et al. Oral anticancer therapy: Management of drug interactions. J Oncol Pract 2015;15:81-90

35

---

---

---

---

---

---

---

---

---

---

**Acid suppression therapy interactions**

PPIs, H2 receptor antagonists, and antacids can effect the absorption of some oral chemotherapy

**EXAMPLES**

- Proton pump inhibitors
  - Due to decreased absorption, PPIs are contraindicated with dasatinib, erlotinib, neratinib and pazopanib
- Histamine H2 receptor antagonists
  - Erlotinib, and nilotinib can be taken 30 hours after or 2 hours before taking a histamine H2-receptor
- Antacids
  - Over-the-counter antacids should be administered 2 hours before or after the administration of acalabrutinib, dasatinib, erlotinib, gefitinib, bosutinib, nilotinib, and ponatinib, and 3 hours before neratinib

Segal EM et al. Oral chemotherapy food and drug interactions: A comprehensive review of the literature. J Oncol Pract 2015;10:e255-268  
Rogala BD et al. Oral anticancer therapy: Management of drug interactions. J Oncol Pract 2015;15:81-90

36

---

---

---

---

---

---

---

---

---

---


**EXAMPLE**

### Herbal products

- Herbal supplements have the potential to cause pharmacodynamic or pharmacokinetic interactions
- Drug-herb interactions can be difficult to evaluate due to limited or lack of data

St. John's Wort

- CYP 3A<sub>4</sub> inducer
- Can decrease the concentration of major substrates of CYP 3A<sub>4</sub> and should be avoided



Segal EM et al. Oral chemotherapy food and drug interactions: A comprehensive review of the literature. J Oncol Pract 2015;13(10):e255-268  
 Rogala BD et al. Oral anticancer therapy: Management of drug interactions. J Oncol Pract 2015;13(8):91-99

37

---

---

---


---

---

---

---

---



**EXAMPLES**

#### Food interactions

- Food can impair or improve the absorption of some oral chemotherapies
- Each drug has specific recommendations if it should be taken with food, without food or with/without food.

- Empty stomach
  - Loperamide should be taken 1 hour before or 1 hour after a meal
- With food
  - Capecitabine should be taken within 30 minutes of a meal
  - Regorafenib should be taken with a low fat breakfast
- Grapefruit
  - Grapefruit is a 3A<sub>4</sub> inhibitor and should be avoided with oral chemotherapy that are substrates of 3A<sub>4</sub>

Segal EM et al. Oral chemotherapy food and drug interactions: A comprehensive review of the literature. J Oncol Pract 2015;13(10):e255-268  
 Rogala BD et al. Oral anticancer therapy: Management of drug interactions. J Oncol Pract 2015;13(8):91-99

38

---

---

---

---

---

---

---

---

### Drug interaction resources

- Manufacturer package insert
- Tertiary drug information databases
  - Lexi-Comp, UpToDate®, Facts and Comparisons, Micromedex
  - [www.drugs.com/drug\\_interactions.html](http://www.drugs.com/drug_interactions.html)
- Herb information
  - Natural Medicines, available through institutional library
    - [www.naturalmedicines.therapeuticresearch.com](http://www.naturalmedicines.therapeuticresearch.com)
  - Memorial Sloan Kettering Cancer Center website *About Herbs, Botanicals & Other Products*
    - [www.mskcc.org/cancer-care/diagnosis-treatment/symptom-management/integrative-medicine/herbs](http://www.mskcc.org/cancer-care/diagnosis-treatment/symptom-management/integrative-medicine/herbs)
  - National Center for Complimentary and Integrative Health
    - [www.nccih.nih.gov](http://www.nccih.nih.gov)

39

---

---

---

---

---

---

---

---



Oral chemotherapy distribution process

- Most oral chemotherapy must be dispensed by a specialty pharmacy
- Provide medications that treat rare or complex diseases and/or are expensive
- Most specialty pharmacies are mail order

40

---

---

---


---

---

---

---

---



41

---

---

---


---

---

---

---

---



42

---

---

---


---

---

---

---

---



43

---

---

---


---

---

---

---

---



44

---

---

---


---

---

---

---

---



45

---

---

---


---

---

---

---

---



46

---

---

---


---

---

---

---

---



47

---

---

---

---

---

---

---

---

**Cost**

- US patients paid an estimated **\$16.2 billion** in out-of-pocket cancer care costs and lost nearly **\$5 billion** in time costs in 2019
- During the first year after a cancer diagnosis
  - Patients aged 65 years or older have an average of **\$2700** in both out-of-pocket and lost time costs
  - Patients < 65 years old had an average **\$5900** in out-of-pocket and lost time costs
- These costs place a large burden on our cancer patients

Kuehni, B. Cancer care creates substantial costs for US patients. JAMA 2022;326:2195.

48

---

---

---

---

---

---

---

---



### Resources to help with drug costs

Uninsured	Commercial Insurance	Government insurance
<ul style="list-style-type: none"> <li>• Manufacturer assistance programs</li> </ul>	<ul style="list-style-type: none"> <li>• Copay cards</li> <li>• Charity grants</li> <li>• Manufacturer assistance programs for under-insured</li> </ul>	<ul style="list-style-type: none"> <li>• Medicare Part D Grants</li> <li>• Manufacturer assistance programs</li> </ul>

49

---

---

---

---

---

---

---

---

### Resources to help with cost

- Charity Grants
  - Patient Access Network Foundation [www.panfoundation.org](http://www.panfoundation.org)
  - Healthwell <https://www.healthwellfoundation.org/>
  - Patient Advocate Foundation <https://copays.org/>
- NeedyMeds [www.needymeds.org](http://www.needymeds.org)
- 1 of US [1ofus.org](http://1ofus.org)
- Leukemia Lymphoma Society [www.lls.org](http://www.lls.org)
- Social Security Compassionate Allowance [www.socialsecurity.gov/compassionateallowances/](http://www.socialsecurity.gov/compassionateallowances/)
- Pharmacists

50

---

---

---

---

---

---

---

---

When poll is active, respond at [polllev.com/uncncln](https://polllev.com/uncncln)  
 Text **UNCLCN** to **22333** once to join

UNC Lineberger Cancer Network

### Which of the following is not the best resource to determine potential drug-drug or drug-herb interactions with an oral chemotherapy medication?

- Medication package insert
- Tertiary databases such as drugs.com
- Tik Tok
- Memorial Sloan Kettering Cancer Center "About Herbs" website

Powered by **Poll Everywhere**

51

---

---

---

---

---

---

---

---



52

---

---

---

---

---

---

---

### Monitoring

- Oral chemotherapy has many potential adverse effects
- Appropriate monitoring is important to prevent and assess side effects

```
graph TD; A[Mechanism of Action] --> B[Cytotoxic]; A --> C[Targeted]; B --> D[Kidney and/or Liver Function]; B --> E[Myelosuppression]; C --> F[Kidney and/or Liver Function]; C --> G[Many potential labs and varies per drug];
```

53

---

---

---

---

---

---

---

### Monitoring

Targeted therapy adverse effects will depend on the drugs "on" targets and "off" targets

Potential toxicities of targeted therapy
Dermatologic
Cardiovascular
Ophthalmologic
Metabolic/Endocrine
Pulmonary
Gastrointestinal
Musculoskeletal
Neurologic
Hematologic
Hepatic
Renal
Other

54

---

---

---


---

---

---

---

### Potential labs/tests to monitor



- CBC/diff
- LFTs
- SCr
- Electrolytes
- Potassium/magnesium
- Lipid panel and glucose
- Lipase/amylase
- Uric acid
- CPK
- TSH
- Pregnancy
- ECG
- ECHO
- Blood pressure

55

---

---

---

---

---

---

---

---

### Where to find required lab testing and intervals

<p><b>Package insert</b></p> <p>Imatinib (Gleevec®)</p> <p>---WARNINGS AND PRECAUTIONS---</p> <ul style="list-style-type: none"> <li>• Edema and severe fluid retention have occurred. Weigh patients regularly and manage unexpected rapid weight gain by drug interruption and diuretics. (5.1, 6.1)</li> <li>• Cytopenias, particularly anemia, neutropenia, and thrombocytopenia, have occurred. Manage with dose reduction, dose interruption, or discontinuation of treatment. Perform complete blood counts weekly for the first month, biweekly for the second month, and periodically thereafter. (5.2)</li> <li>• Severe congestive heart failure and left ventricular dysfunction have been reported, particularly in patients with comorbidities and risk factors. Monitor and treat patients with cardiac disease or risk factors for cardiac failure. (5.3)</li> <li>• Severe hepatotoxicity, including fatalities may occur. Assess liver function before initiation of treatment and monthly thereafter or as clinically indicated. Monitor liver function when combined with chemotherapy known to be associated with liver dysfunction. (5.4)</li> <li>• Grade 3+ hemorrhage has been reported in clinical studies in patients with newly diagnosed CML and with GIST. GI tumor sites may be the source of GI bleeds in GIST. (5.5)</li> </ul> <p><small><a href="https://www.accessdata.fda.gov/drugatfd/label/2005/021980a1/1b1.pdf">https://www.accessdata.fda.gov/drugatfd/label/2005/021980a1/1b1.pdf</a></small></p>	<p><b>Tertiary drug information databases</b></p> <ul style="list-style-type: none"> <li>• Lexi-Comp</li> <li>• UpToDate®</li> <li>• Facts and Comparisons</li> <li>• Micromedex</li> <li>• Drugs.com</li> <li>• DailyMed</li> </ul>
--	--

56

---

---

---

---

---

---

---

---

### Example: Imatinib

- **Pretreatment Screening**
  - Complete blood cell count (CBC)
  - Baseline liver and renal function
  - Consider performing an echocardiogram and determining serum troponin concentrations in patients with hyper eosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL), and in patients with myelodysplastic/myeloproliferative diseases or aggressive systemic mastocytosis associated with high eosinophil levels. If results of the echocardiogram or serum troponin concentrations are abnormal, consider prophylactic use of systemic corticosteroids.
  - Verify pregnancy status in females of reproductive potential
- **Patient Monitoring**
  - Monitor for signs or symptoms of fluid retention (e.g., weight gain) regularly during therapy
  - Monitor CBC weekly for the first month of therapy, every other week during the second month, and periodically (e.g., every 2–3 months) thereafter as clinically indicated
  - Carefully monitor patients with cardiac disease or risk factors for cardiac disease for signs and symptoms of cardiac toxicity or renal failure
  - Carefully monitor patients with a history of renal failure for signs and symptoms of cardiac toxicity or renal failure
  - Monitor liver function monthly or as clinically indicated during therapy
  - Monitor renal function during therapy
  - Monitor serum TSH concentrations in patients receiving levothyroxine replacement therapy following thyroidectomy
  - In pediatric patients, monitor bone growth and development
  - Monitor patients with high tumor burden or those with a high proliferative rate for TLS <https://www.drugs.com/monograph/imatinib.html>

57

---

---

---

---

---

---

---

---

Monitoring CML TKIs						
	Imatinib	Nilotinib	Dasatinib	Bosutinib	Ponatinib	Asciminib
CBC	X (weekly x2 mo → biweekly x2 mo → periodically)	X (biweekly x2 mo → monthly)	X (weekly x2 weeks → q3 months)	X (weekly x2 mo → monthly)	X (biweekly x3 mo → monthly)	X (biweekly x3 mo → monthly)
LFTs	X (baseline → monthly)	X (baseline → monthly)	X (baseline → periodically)	X (monthly x3 → periodically)	X (baseline → monthly)	
SCr	X (baseline → periodically)			X (baseline → periodically)		
Electrolytes	X (baseline → periodically)	X (baseline → periodically)	X (baseline → periodically)		X (baseline → periodically)	
Lipid profile & glucose		X (baseline → periodically)				
Lipase & Amylase		X (baseline → monthly)			X (biweekly x2 mo → monthly)	X (baseline → monthly)
Uric Acid		X (baseline)			X (baseline)	
ECG		X (baseline → periodically)	X (baseline → q3mo x2)			
Pregnancy	X	X	X	X	X	X

58

---

---

---

---

---

---

---

---

---

---

Monitoring CDK 4/6 Inhibitors			
	Palbociclib	Abemaciclib	Ribociclib
CBC	X (baseline, biweekly x2 mo, then as indicated)	X (baseline, biweekly x2 mo → monthly x2 mo, then as indicated)	X (baseline biweekly x2 mo → monthly x4 mo, then as indicated)
LFTs		X (baseline, biweekly x2 mo → monthly x2 mo, then as indicated)	X (baseline biweekly x2 mo → monthly x4 mo, then as indicated)
SCr		X (baseline → periodically)	
Electrolytes			X (baseline → monthly x6, then as indicated)
ECG			X (baseline → q3weeks x2), then as indicated

59

---

---

---

---

---

---

---

---

---

---

### Adherence

**Definition:**  
"the degree or extent of conformity of the recommendations about day-to-day treatment by the provider with respect to timing, dosage, and frequency"

Optimal adherence and persistence occurs when a patient follows his/her prescribed treatment regimen

Consequences of non-adherence

Poor patient outcomes

Increased toxicities

Increased health care costs

Cramer JA et al. Medication compliance and persistence terminology and definitions. Value Health 2008;11:44-47  
Buddy, K et al. Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin 2009;59:56-66

60

---

---

---

---

---

---

---

---

---

---

### Consequences of non-adherence

- Women diagnosed with hormone-sensitive breast cancer prescribed adjuvant endocrine therapy for 5 years
  - N = 8769 women
  - 31.5% discontinued medication early
  - Of the 6000 women who continued the medication for the full time, 28% took < 80% of doses
  - Discontinuation and adherence were independent predictors of mortality

Hershman DL et al. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat. 2013;136:519-527.

61

---

---

---

---

---

---

---

---

---

---

### Consequences of non-adherence

- Patients with CML on imatinib
  - Patients with adherence rate > 90% were associated with a major molecular response (MMR)
  - Probability of MMR in patients with adherence rate of > 90% = 93.7%
  - Probability of MMR in patients with adherence rate of ≤ 90% = 13.9%

Marin D et al. Adherence is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib 2010. JCO 2010;28:2381-2388

62

---

---

---

---

---


---

---

---

---

---



63

---

---

---

---

---

---

---

---

---

---

### Adherence Assessment

**Ask**

Since I last saw you, how many doses of your medication do you think you missed?

**Look for signs/predictors of non-adherence**

- Missed appointments
- Unfilled prescriptions
- Adverse effects
- High medication cost
- Lack of belief or understanding of treatment
- Psychological factors such as depression

64

---

---

---

---

---

---

---

---

### Improving adherence

Barriers	Solutions
Forgetfulness	Alarm Clock/Phone Alarm
	Phone apps
	Family members
Side Effects	Close Follow-Up
	Early Management
Questions	Re-education
	Empowerment
Cost	Medication Assistance
	Written Care Plan
Complex Regimen	Calendars
	Simplify regimen whenever possible

65

---

---

---

---

---

---

---

---

When poll is active, respond at [polllev.com/uncncln](https://polllev.com/uncncln)  
 Text **UNCNCLN** to **22333** once to join

UNC Lineberger Cancer Network

Which of the following is a sign of non-adherence to a medication?

Patient tolerates the medication with few adverse effects

Medication has a high cost

Patient is engaged in his/her treatment

Prescriptions are filled regularly and on time

Powered by Poll Everywhere

Start the presentation to see live content. For screen share software, share the entire screen. Get help at [polllev.com/help](https://polllev.com/help)

66

---

---

---

---

---

---

---

---



67

---

---

---


---

---

---

---

---



68

---

---

---


---

---

---

---

---



69

---

---

---

---


---

---

---

---

### Safe storage



- Store in a safe place away from children and pets
- Store medications away from sunlight, humid bathrooms, or other areas that may have fluctuations in temperature
- Read labels - some oral chemotherapy must be stored in original container (e.g. regorafenib) or refrigerated (e.g. oral etoposide, trametinib)
- If traveling, store in original, pharmacy-labelled container

https://www.ncoda.org/wp-content/uploads/2019/09/Safe-Handling-of-Oral-Chemo-1. Accessed 12/12/22

70

---

---

---

---

---

---

---

---

### Safe disposal

- Don't discard unused tablets/capsules down the toilet
- Dispose in local medication disposal sites or drop boxes
- May mix whole tablets with something unpalatable (e.g. coffee grounds) and place in a container with lid or double sealable storage bags prior to placing in regular trash
- Celgene provides packaging so patients may return unused lenalidomide, pomalidomide, and thalidomide

https://www.ncoda.org/wp-content/uploads/2019/09/Safe-Handling-of-Oral-Chemo-1. Accessed 12/12/22

71

---

---

---

---

---

---

---

---

### Oral chemotherapy resources

- Hematology/Oncology Pharmacy Association (HOPA)
  - Oral chemotherapy resources
    - [www.hopax.org/images/hopa/resource-library/guidelines-standards/Oral\\_Chemo\\_Resources\\_Web\\_Outline.pdf](http://www.hopax.org/images/hopa/resource-library/guidelines-standards/Oral_Chemo_Resources_Web_Outline.pdf)
- Oncology Nursing Society
  - Oral Anticancer Medication Toolkit
    - [www.ons.org/clinical-practice-resources/oral-adherence-toolkit](http://www.ons.org/clinical-practice-resources/oral-adherence-toolkit)
- Drug.com
  - Drug monographs
    - [www.drugs.com/](http://www.drugs.com/)
- Daily Med
  - Drug monographs
    - [www.dailymed.nlm.nih.gov/dailymed](http://www.dailymed.nlm.nih.gov/dailymed)
- Pharmacists

72

---

---

---

---

---

---

---

---





73

---

---

---

---

---

---

---

---



74

---

---

---

---

---

---

---

---



75

---

---

---

---


---

---

---

---

**THANK YOU!**



**UNC** | LINEBERGER COMPREHENSIVE  
CANCER CENTER

**UNC Lineberger Cancer Network**

**The Telehealth Team**

Tim Poe, Director

<small>Veneranda Oburo, Technology Support Specialist</small>	<small>Andrew Dodgson, DPT, Continuing Education Specialist</small>
<small>Jon Powell, PhD, Continuing Education Specialist</small>	<small>Nadja Brown, Informatics Administrative Support Specialist</small>
<small>Oliver Marth, Technology Support Technician</small>	<small>Patrick Muscarella, Technology Support Technician</small>

76

---

---

---

---

---

---

---

---

**UPCOMING LIVE WEBINARS**

<p><b>PATIENT CENTERED CARE</b></p> <p><small>Webinar</small></p> <p><b>March 8</b></p> <p><b>12:00 PM</b></p>	<p><b>Integrating the Caregiver as a Member of the Multidisciplinary Care Team</b></p> <p><small>Erin Kent, PhD, MSc Loretta Muss, RN, BA</small></p>
<p><b>ADVANCED PRACTICE PROVIDER</b></p> <p><small>Webinar</small></p> <p><b>March 15</b></p> <p><b>4:00 PM</b></p>	<p><b>What Is Cancer Rehabilitation and How Can it Help My Patients?</b></p> <p><small>Sasha E. Knowlton, MD</small></p>
<p><b>RESEARCH TO PRACTICE</b></p> <p><small>Webinar</small></p> <p><b>March 22</b></p> <p><b>12:00 PM</b></p>	<p><b>Clinical Updates in Breast Oncology</b></p> <p><small>Emily Ray, MD, MPH</small></p>

Complete details on upcoming LIVE webinars:  
[learn.unclcn.org/live-webinars](http://learn.unclcn.org/live-webinars)

77

---

---

---

---

---

---

---

---

**Spread the Word**

**LIVE CCO WEBINARS**

UNC Lineberger Cancer Network

**NORTH CAROLINA COMMUNITY COLLEGE** Webinar

ONCOLOGY WEBINARS

<p><b>February 21</b></p> <p><b>4:00 PM</b></p>	<p><b>Caring for Patients with Head and Neck Cancers</b></p> <p><small>Trevor Hackman, MD, FACS Catherine J. Lumley, MD</small></p>
<p><b>March 21</b></p> <p><b>4:00 PM</b></p>	<p><b>Caring for Patients with GI Cancers</b></p> <p><small>Melanie N. Allard, DNP, APRN, FNP-BC, CCRN</small></p>

For a complete listing and details on coming events visit:  
[learn.unclcn.org/cco](http://learn.unclcn.org/cco)

78

---

---

---

---

---

---

---

---

**SELF-PACED, ONLINE COURSES**

**PATIENT CENTERED CARE**  
 Occupational Therapy for Cancer Survivors  
 Farrell Wiggins, MS, OTR/L  
 Alexis Petteway, MS, OTR/L

**RESEARCH TO PRACTICE**  
 Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC): An Evolving Poor-risk Subgroup of High Unmet Need  
 Joshua F. Zeidner, MD

**PATIENT CENTERED CARE**  
 Providing LGBTQ Friendly Care in Oncology  
 Patti Morfield, RN, BSN, OCN

Today's webinar will be available in March 2023 as a FREE, Self-Paced, Online Course. Complete details on Self-Paced Online Courses: [learn.unccln.org/spoc](http://learn.unccln.org/spoc)

79

---

---

---

---

---

---

---

---

**THANK YOU FOR PARTICIPATING!**

**UNC Lineberger Cancer Network**

Email: [unccln@unc.edu](mailto:unccln@unc.edu)  
 Call: (919) 445-1000

Send us an email to sign up for our monthly e-newsletter.  
 Check us out at [unccln.org](http://unccln.org)

 [facebook.com/unccln](https://www.facebook.com/unccln)  [@unc\\_cn](https://twitter.com/unc_cn)

80

---

---

---

---

---

---


---

---

**AFTER THE WEBINAR**

To collect CE Credit, please wait for UNCLCN to end the Zoom video.

The Learning Portal only receives Zoom attendance data after the Zoom video has ended.



81

---

---

---

---

---

---

---

---